GLP-1 therapies, or glucagon-like peptide-1 analogs , represent a remarkable shift in how we treat high blood sugar. These prescription drugs function to mimicking the body’s own GLP-1 substance , which promotes insulin release and lowers blood sugar production . Beyond blood sugar regulation, trials suggest that GLP-1 receptor agonists may also